Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 2Rectal Neoplasms 1Neurofibromatosis 1 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 31Fluorouracil 31Leucovorin 29Irinotecan 23Cetuximab 20Bevacizumab 16Capecitabine 13Gemcitabine 11pembrolizumab 8Folfox protocol 7Cisplatin 7Carboplatin 7Paclitaxel 6Nivolumab 6Cyclophosphamide 6trifluridine tipiracil drug combination 5cediranib 5Erlotinib Hydrochloride 5adagrasib 4Ipilimumab 4IFL protocol 4Floxuridine 4Bortezomib 4veliparib 3trametinib 3sargramostim 3poly ICLC 3binimetinib 3Trifluridine 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Colonic Neoplasms × encorafenib × Clear all
NCT04044430 2023-01-09

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

University of California, San Francisco

Phase 1 Terminated
2 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡